The Nexus of Insight: Where Competitive Intelligence Meets Strategy
- Tina Witte
- 7 days ago
- 4 min read
In my time leading the Life Sciences Practice Area at Fletcher, I’ve seen just how vastly differently organizations choose to anchor their Competitive Intelligence efforts. Some operate absent a formal CI function at all, while others are in the infancy stages of a more formidable buildout. And then there are the companies that have made substantive investments altogether, standing up full departments and giving CI a real seat at the executive table.
This often prompts me to wonder, “Where does CI belong?"
You’ve seen my previous blog and LinkedIn posts about the continuing unrest (volatility?) that the pharma and biotech sector continues to endure. A single clinical trial pivot or a surprise M&A move can and has quite literally shifted billions in market cap. Decisions to go/no-go on developmental programs have also seen divestiture or, in some cases, complete abandonment. Regardless of the size of the organization, none are immune to these phenomena.
Formally housed or not, one thing is for certain. The results produced by CI inform confident and deliberate strategic decisions.
Whether a nimble biotech or a multi-billion-dollar big pharma, the "home" of CI typically dictates the flavor of the insights produced and, ultimately, how those insights drive influence at the highest leadership levels.
The Functional Landscape: Where the Desk Sits
Historically, CI has been a bit elusive insofar as where it is potentially situated to be optimized. Today, we generally see it integrated into three specific areas:
Commercial & Brand Marketing: The most common "tactical" home. Here, CI focuses on the near(er)-term opportunities and horizons: new product planning, the next launch, sales force effectiveness, and counter-messaging/positioning against competitors. High-octane and highly responsive to market fluctuations.
Strategy & Corporate Development: In this silo, the lens widens. CI teams zoom out to the (example) 5-to-10-year (strategic) horizon, evaluating therapeutic area (TA)
entries, licensing opportunities, and "white spaces". Reporting relationships often report directly to the Chief Strategy Officer or Head of Business Development.
Medical Affairs & R&D: Increasingly, we see CI embedded deep within the SciOps engine. Here, the "competitors" aren't just products on a shelf; they are mechanisms of action (MoAs) and clinical trial designs. Technical in nature, CI here is rigorous and crucial for avoiding "me-too" pipelines before they cost hundreds of millions in lackluster or failed developments.
Cross-Functional Weaving and Reporting Lines
Regardless of its placement on the org chart, CI is the ultimate cross-functional "glue." I like to refer to it as “the connective tissue,” and I often tell my clients that a CI lead who stays at the desk is an injustice to the potential and vitality of the role. To truly drive value, the function should bridge the gap between science and the stock exchange.
The most effective and thriving examples I have seen are those that offer unfiltered access to leadership. When CI reports into multiple hierarchical layers, the messages and insights are often diluted or, worse, present biased to support existing brand narratives. I’ve seen emerging innovative models take shape, such as centralized CI Centers of Excellence, serving as an internal consultancy. These might report into Global Strategy or Strategy Leads, but maintain "embedded" specialists representing each major Brand or TA to ensure the nuances of a specific disease state are never lost in translation.
Generally reputed to be among the most collaborative roles and functions, regardless of where embedded, optimally, this occurs when CI has a permanent seat and voice during Target Product Profile (TPP) development and War Gaming/Scenario Planning Exercises sessions. By connecting Clinical, Regulatory, and Commercial, CI ensures the company isn’t developing a drug for yesterday’s market.
The New Frontier: AI and the Efficiency Revolution
It’s a fool’s game to dismiss the modern intelligence landscape without addressing the biggest technological catalyst of our time: Generative AI and Machine Learning.
The "information gathering" phase of CI is undergoing a radical shift, to put it gently. Moving away from manual data scraping toward autonomous monitoring systems, for starters. This shift is what allows CI to move from a support function to a strategic partner.
AI-Driven Signal Detection: New tools can now synthesize thousands of clinical trial updates, patent filings, relevant news bytes, conference abstracts, among others, in real-time; and are also able to flag or alert to "disruptive signals" before a human analyst finishes reviewing the source links.
Primary CI Tech: The rise and volume of sophisticated platforms enabling primary research, blinded expert interviews, and KOL surveys are escalating daily.
The Human Element: An important note; crucially, AI is not and should not replace the CI professional. If anything, it should liberate them. By automating the collection, we allow the intelligence, the "so what?", to take center stage. The value now lies in the synthesis: the ability to better communicate to a CEO and strategy leaders the implications of the intelligence gathered, such as exactly why a competitor’s Phase II data matters to their specific pipeline.
The Bottom Line: Value Over Venue
Ultimately, the debate over whether CI sits in Marketing or Strategy is secondary to the culture of intelligence within the firm.
The enormity of value derived from CI is found in its ability to de-risk decision-making. In Life Sciences, we play a high-stakes game where the "cost of being wrong" is astronomical. Whether the CI team is a two-person powerhouse in a biotech startup or a global department of fifty, their value is realized when they move the organization from a reactive posture ("Why did they do that?") to a proactive one ("We knew they would do that, and here is our move").
When CI is properly empowered, it acts as the organization’s nervous system, sensing changes in the environment and triggering the right response across every department. Regardless of where the “desk” sits, as long as the voice is heard at the highest levels of strategy.
What about your organization? Are your CI insights trapped in a functional silo, or are they driving the high-level strategy your pipeline deserves? I’d love to hear how your teams are structuring for the next wave of competition.
Let Fletcher Help You Apply Competitive Intelligence To Elevate Your Strategic Advantage!
To explore the benefits and opportunities for optimizing CI at your organization, regardless of where your CI function sits, contact Tina Witte, SVP of Life Sciences, today. Her team offers deep expertise across CI, MI, Strategic Decision Support, and Life Sciences, enabling organizations to anticipate change, refine decision‑making, and execute strategy with confidence.
